Checking heart arteries with CT scans in people with leg artery disease
Tests a heart scan and blood-flow analysis in adults with leg artery disease.
Plain-language title generated from the registry record
Registry title: Selective Coronary Revascularization in Peripheral Artery Disease Patients (SCOREPAD Trial)
Key facts
- Where
- Riga, LatviaSee the site
Where in Latvia
- Pauls Stradins Clinical University HospitalRiga, LatviaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pauls Stradins Clinical University Hospital
- Trial code
- NCT06250790
- Record updated
- 16 February 2024
- Original description
The primary objective of this study is to determine whether among symptomatic Peripheral Arterial Disease (PAD) patients with no known Coronary Artery Disease (CAD) who had undergone lower-extremity revascularization, a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.Read full original descriptionShow less
Selective Coronary Revascularization in Peripheral Artery Disease Patients After Lower-extremity Revascularization (SCOREPAD Trial)
The primary objective of this study is to determine whether among symptomatic Peripheral Arterial Disease (PAD) patients with no known Coronary Artery Disease (CAD) who had undergone lower-extremity revascularization, a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.
Inclusion: Inform consent obtained before any study-related activities; Age above or equal to 50 years with symptomatic lower extremity PAD (severe claudication or chronic limb-threatening ischemia, Rutherford 3,4,5) which has been successfully revascularized by open surgical or endovascular procedure within the past 14 days; Willing and able to undergo coronary CTA scan within 14 days of randomization and agrees to submission of CTA data set for HeartFlow FFRct analysis with results made available to treating physician.
Exclusion: Known CAD, history of MI, prior coronary revascularization (PCI or CABG); Severe arrhythmia, prior pacemaker or internal defibrillator lead implantation; Participation in any interventional clinical study within 30 days prior to screening; History of severe asthma, severe or bronchodilator-dependent Chronic obstructive pulmonary disease (COPD); Severe congestive heart failure (NYHA III or IV); Subjects with known anaphylactic allergy to iodinated contrast; Any active, serious, life-threatening disease with a life expectancy of less than 2 years; Any active infection; Known history of 2nd or 3rd degree heart block; sick sinus syndrome; long QT syndrome; Impaired chronic renal function (EPI-Glomerular Filtration Rate (GFR)<30ml/min); Patient underwent coronary angiography or coronary CTA before the randomization; Pregnancy or unknown pregnancy status in subject of childbearing potential; Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure <90 mmHg, or acute pulmonary edema; Inability to comply with study procedures; Contraindication for guideline-guided longterm antiplatelet/anticoagulation regime after PCI/CABG.